6-溴-2,4-二甲基-3-羟基吡啶 | 1062541-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-溴-2,4-二甲基-3-羟基吡啶
• 英文名称: 6-bromo-2,4-dimethyl-3-pyridinol
• 英文别名: 6-bromo-2,4-dimethylpyridin-3-ol；6-bromo-2,4-dimethyl-3-hydroxypyridine
• CAS: 1062541-78-9
• 化学式: C₇H₈BrNO
• 分子量: 202.051
• InChiKey: GLMXOYJTFKWRKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-溴-2,4-二甲基-3-羟基吡啶 在 叔丁基锂 、 碲化氢 、 氧气 作用下， 以 四氢呋喃 、 正戊烷 、 水 为溶剂， 生成
  参考文献：
  名称：

  Catalytic Chain-Breaking Pyridinol Antioxidants

  摘要：

  The synthesis of 3-pyridinols carrying alkyltelluro, alkylseleno, and alkylthio groups is described together with a detailed kinetic, thermodynamic, and mechanistic Study of their antioxidant activity. When assayed for their capacity to inhibit azo-initiated peroxidation of linoleic acid in a water/chlorobenzene two-phase system, tellurium-containing 3-pyridinols were readily regenerable by N-acetylcysteine contained in the aqueous phase. The best inhibitors quenched peroxyl radicals more efficiently than alpha-tocopherol, and the duration of inhibition was limited only by the availability of the thiol reducing agent. fn homogeneous phase, inhibition of styrene autoxidation absolute rate constants k(inh) for quenching of peroxyl radical were as large as 1 x 10(7) M-1 s(-1), thus Outperforming the best phenolic antioxidants including alpha-tocopherol. Tellurium-containing 3-pyridinols could be quantitatively regenerated in homogeneous phase by N-tert-butoxycarbonyl cysteine methyl ester, a lipid-soluble analogue of N-acetylcysteine. In the presence of an excess of the thiol, a catalytic mode of action was observed, similar to the one in the two-phase system. Overall, compounds bearing the alkyltelluro moiety ortho to the OH group were much more effective antioxidants than the corresponding para isomers. The origin of the high reactivity of these compounds was explored using pulse-radiolysis thermodynamic measurements, and a mechanism for their unusual antioxidant activity was proposed. The tellurium-containing 3-pyridinols were also found to catalyze reduction of hydrogen peroxide in the presence of thiol reducing agents, thereby acting as multifunctional (preventive and chain-breaking) catalytic antioxidants.

  DOI：

  10.1021/jo902226t
• 作为产物：
  描述：

  2,4-二甲基-3-羟基吡啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 以61%的产率得到6-溴-2,4-二甲基-3-羟基吡啶
  参考文献：
  名称：

  杂芳族化合物合成的闭环复分解：评估吡啶和哒嗪的路线

  摘要：

  闭环烯烃复分解（RCM）已用于稠密和不同取代的吡啶和哒嗪骨架的有效合成。已经研究了合适的复分解前体的途径，并探讨了复分解步骤的范围。复分解产物通过消除合适的离去基团而充当目标杂芳族结构的前体，这还通过充当氮上的保护基团而促进了较早的步骤。在芳构化之前和之后，复分解产物的进一步功能化都是可能的。最终结果是强有力的从头合成高度取代的杂芳族骨架的策略。

  DOI：

  10.1016/j.tet.2009.07.076

文献信息

• Synthesis of substituted pyridines and pyridazines via ring closing metathesis
  作者：Timothy J. Donohoe、Lisa P. Fishlock、José A. Basutto、John F. Bower、Panayiotis A. Procopiou、Amber L. Thompson

  DOI：10.1039/b904363b

  日期：——

  RCM can be used to make aromatic heterocycles, namely pyridines and, for the first time, pyridazines; the key step after RCM involves elimination of sulfinate to provide the aromatic system.

  RCM可用于制造芳香族杂环，即吡啶，并首次用于制备哒嗪；RCM之后的关键步骤涉及消除亚磺酸盐以提供芳族体系。
• NEW COMPOUNDS 574
  申请人：HOLENZ Jorg

  公开号：US20100125081A1

  公开（公告）日：2010-05-20

  The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及具有式（I）的新化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理学，如唐氏综合征、β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退化，包括混合性血管性和退行性起源的痴呆、老年前期痴呆、老年痴呆和与帕金森病、进行性上丘脑麻痹或皮质基底节变性相关的痴呆。
• [EN] COMPOUNDS COMPRISING A 3-PYRIDINOL OR 5-PYRIMIDINOL RING HAVING AN ORGANOSELENO OR ORGANOTELLURO SUBSTITUENT FOR USE AS ANTIOXIDANTS<br/>[FR] COMPOSÉS COMPRENANT UN NOYAU 3-PYRIDINOL OU 5-PYRIMIDINOL À SUBSTITUANT ORGANOSÉLÉNO OU ORGANOTELLURO UTILISÉS COMME ANTI-OXYDANTS
  申请人：KAROLINSKA INST INNOVATIONS AB

  公开号：WO2009144253A1

  公开（公告）日：2009-12-03

  Compounds comprising a 3-pyridinol or 5-pyrimidinol ring carrying an organoseleno- or organotelluro- substituent on the pyridine or pyrimidine ring, exhibit useful antioxidant properties. The compounds may for example be in accordance with the following formula (I) as defined herein. Catalytic chain-breaking and hydroperoxide decomposing antioxidant properties are also disclosed. Furthermore the compounds may be used in combination with a reducing agent. The compounds are useful for the stabilization of man-made and natural materials, or for the prevention or treatment of disorders caused by or involving free radical-mediated or oxidative tissue damage.

  含有3-吡啶醇或5-嘧啶醇环，在吡啶或嘧啶环上带有有机硒或有机碲取代基团的化合物，表现出有用的抗氧化性能。这些化合物可能符合以下定义的化学式(I)。还披露了催化链断裂和过氧化物分解抗氧化性能。此外，这些化合物可以与还原剂结合使用。这些化合物可用于稳定人造和天然材料，或用于预防或治疗由自由基介导或氧化组织损伤引起的疾病。
• NEW COMPOUNDS 578
  申请人：HOLENZ Jörg

  公开号：US20100125082A1

  公开（公告）日：2010-05-20

  The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式(I)的新化合物及其药物组合物。此外，本发明涉及用于治疗和/或预防与Aβ相关的病理学，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病，进行性上核性麻痹或皮层基底变性相关的痴呆有关的治疗方法。
• Substituted Isoindoles
  申请人：HOLENZ Jörg

  公开号：US20110319426A1

  公开（公告）日：2011-12-29

  The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式（I）的新型化合物及其制药组合物。此外，本发明涉及治疗和/或预防与Aβ相关的病理学，例如唐氏综合症、β-淀粉样蛋白血管病，例如脑淀粉样血管病或遗传性脑出血，与认知障碍有关的疾病，例如轻度认知障碍（MCI）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合的血管性和退行性起源的痴呆症、老年前期痴呆症、老年痴呆症和与帕金森病、进行性核上性麻痹或皮质基底节变性有关的痴呆症的治疗方法。